<?xml version="1.0"?>
<trials subjects="1">
  <Triall>
    <main>
      <UTRN />
      <trial_id>ChiCTR-OPB-15005956</trial_id>
      <utrn />
      <reg_name>ChiCTR</reg_name>
      <date_registration>2015-02-09</date_registration>
      <primary_sponsor>Southwest Hospital, Third Military Medical University</primary_sponsor>
      <public_title>Effective and safety of human umbilical cord derived mesenchymal stem cells (HU - MSCs) infusion treatment of refractory connective tissue diseases</public_title>
      <acronym />
      <scientific_title>Effective and safety of human umbilical cord derived mesenchymal stem cells (HU - MSCs) infusion treatment of refractory connective tissue diseases</scientific_title>
      <Scientific_acronym />
      <date_enrolment>2014-12-01</date_enrolment>
      <type_enrolment />
      <target_size>HU-MSCs treatment group:30;</target_size>
      <recruitment_status>Recruiting</recruitment_status>
      <url>http://www.chictr.org.cn/showproj.aspx?proj=10416</url>
      <study_type>Observational study</study_type>
      <study_design>Before-After control</study_design>
      <phase>II (Phase II study)</phase>
      <hc_freetext>connective tissue diseases</hc_freetext>
      <i_freetext>HU-MSCs treatment group:HU-MSCs intravenous infusion ;</i_freetext>
      <results_actual_enrolment />
      <results_date_completed />
      <results_url_link />
      <results_summary />
      <results_date_posted />
      <results_date_first_publication />
      <results_baseline_char />
      <results_participant_flow />
      <results_adverse_events />
      <results_outcome_measures />
      <results_url_protocol />
      <results_IPD_plan />
      <results_IPD_description />
    </main>
    <contacts>
      <contact>
        <type>Scientific</type>
        <firstname>Bing Zhong</firstname>
        <middlename />
        <lastname />
        <address>Department of Rheumatology, Southwest Hospital, Third Military Medical University, Chongqing</address>
        <city />
        <country1 />
        <zip>400038</zip>
        <telephone>+86 18203063388</telephone>
        <email>dune_zhong@163.com</email>
        <affiliation>Department of Rheumatology, Southwest Hospital, Third Military Medical University, Chongqing</affiliation>
      </contact>
      <contact>
        <type>Public</type>
        <firstname>Yong Wang</firstname>
        <middlename />
        <lastname />
        <address>Department of Rheumatology, Southwest Hospital, Third Military Medical University, Chongqing</address>
        <city />
        <country1 />
        <zip>400038</zip>
        <telephone>+86 18983007129</telephone>
        <email>wangyongjhy@126.com</email>
        <affiliation />
      </contact>
    </contacts>
    <countries>
      <country2>China</country2>
    </countries>
    <criteria>
      <inclusion_criteria>1. Patient has signed informed consent for mesenchymal stem cell treatment and is willing to return for follow-up visits; 
2. Age range 18 to 70 years,gender unlimited;
3. Patients with connective tissue diseases, such as rheumatoid arthritis, systemic lupus erythematosus, dermatomyositis/polymyositis, systemic sclerosis, primary sj?gren syndrome or systemic vasculitis;
4. patients were inadequate response for the conventional therapy.</inclusion_criteria>
      <agemin>18</agemin>
      <agemax>70</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Patients were excluded from this study for any of the following reasons: 
age &lt;18 years or &gt;70 years; 
pregnant or lactating, if applicable; 
known to be allergic to any test medication; 
serious concomitant cardiac, cerebral, hepatic, renal, hematological or endocrine disorders; 
impaired consciousness or psychiatric disorders; 
complicating severely active infection; 
HIV carrier; 
drug addiction; 
participation in any other clinical studies within the previous three months; 
or other reasons at the discretion of investigators.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code />
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword />
    </health_condition_keyword>
    <intervention_code>
      <i_code>;</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword />
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>ESR;CRP;T cell subgroup count;IgG IgM IgA;DAS28 score;</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome />
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name />
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id />
        <issuing_authority />
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Clinical research fund of Southwest Hospital, Third Military Medical University</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2014-09-23</approval_date>
        <contact_name />
        <contact_address />
        <contact_phone />
        <contact_email />
      </ethics_review>
    </ethics_reviews>
  </Triall>
</trials>